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PreeclampsiaThe present study aimed to evaluate microparticles (MPs) from different sources in women with severe pre-
eclampsia (PE) compared with normotensive pregnant women and non-pregnant women. This case–control
study evaluated 28 pregnant women with severe PE, 30 normotensive pregnant women, and 29 non-pregnant
women. MPs from neutrophils, endothelial cells, monocytes, platelets, leukocytes, erythrocytes, and
syncytiotrophoblast were evaluated using ﬂow cytometry. A higher total number of MPs were observed in
women with severe PE compared with normotensive pregnant women and non-pregnant women (P=0.004
and P=0.001, respectively). MPs derived from erythrocytes were increased inwomenwith severe PE compared
with normotensive pregnant women (P=0.002). A trend towards association was observed between platelet
count and the number of MPs derived from platelets (P=0.09) in severe PE group. A positive correlation was
also found between the number of endothelial cell-derived MPs and the number of platelet-derived MPs,
leukocyte-derived MPs, neutrophil-derived MPs, and lymphocyte-derived MPs (Pb0.05) in severe PE pregnant
women. MP counts can be increased in severe PE, and erythrocyte and endothelial cell-derived MPs seem to
be associated to severe PE.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Preeclampsia (PE) is a pregnancy-speciﬁc syndrome characterized
clinically by hypertension and proteinuria after 20 weeks gestation
[1,2]. The etiology of PE remains unknown, but it is a multifactorial dis-
order. The clinical spectrum ranges from mild to severe [3,4]. In its se-
vere form, PE is an important cause of maternal and fetal morbidity
and mortality worldwide [3,5]. The origin of PE remains enigmatic de-
spite considerable research, but the placenta undoubtedly plays a role
in its pathogenesis because delivery inevitably leads to recovery [6,7].
Pregnancy is a controlled inﬂammatory state. It is believed that an
excessive systemic inﬂammatory response is the basis of clinical mani-
festations of PE, but the causes of this inﬂammatory response in normal
pregnancy and PE are not known [8,9]. Some studies have shown that
all network components of intravascular inﬂammation (leukocytes,
endothelial cells, and the coagulation cascade) contribute to the exacer-
bation of the inﬂammatory response in PE [10]. In addition to placental
cytokines and angiogenic factors, apoptotic fragments released into theises Clínicas e Toxicológicas,
erais, Avenida Antônio Carlos,
ais, Brazil. Tel.: +55 31 3409
.
evier OA license.maternal blood are candidates that trigger this systemic inﬂammatory
process [9,11–13].
Microparticles (MPs) are vesicles (0.1–1 μm) that are shed from the
plasmamembranes of several cell types in response to activation or ap-
optosis. The initial step in their formation is membrane remodeling
with the formation of blebs. This step requires increased intracellular
calcium levels resulting in the rearrangement and loss of phospholipidic
membrane asymmetry with externalization of phosphatidylserine.
Concomitant to the loss ofmembrane asymmetry, calcium-sensitive en-
zymes are activated and promote cleavage of the cytoskeletal ﬁlaments,
leading to bleb formation on the membrane and MP release.
MPs are considered potent vectors of biological information and
protagonists of cellular communication networks, such as the induc-
tion of endothelial modiﬁcations, inﬂammation, differentiation, and
angiogenesis, because they mediate cell–cell communication by
transferring mRNAs andmicroRNA from the cell of origin to the target
cells [14–16].
MPs of various cellular origins are found in the plasma of healthy
subjects, and their amounts increase under pathological condi-
tions [15]. Several groups have reported elevated circulating levels
of MPs during pregnancy, but this increase is especially important in
preeclampsia, suggesting their involvement in the hypertension asso-
ciated with this disease [17,18]. Measurement of MP phospholipid
content (mainly phosphatidylserine) has allowed their quantiﬁcation
and characterization [15].
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PE. Because severe PE is associated with procoagulant and pro-
inﬂammatory states, studies involving MP pathways should be
conducted to clarify a possible role of MPs in PE.
2. Material and methods
2.1. Study design
This study included 87women: 28 pregnant womenwith severe PE,
30 normotensive pregnant women, and 29 non-pregnant women.
Women with severe preeclampsia were enrolled from Maternidade
Odete Valadares, Santa Casa de Misericórdia de Belo Horizonte, and
Hospital Municipal Odilon Behrens — Belo Horizonte/Brazil and in-
cluded into the study. Normotensive pregnant women and non-
pregnant women were enrolled from Centro de Saúde Guanabara,
Betim/Brazil. Clinical data were obtained from the patients' medical
records.
2.1.1. Inclusion criteria
Severe PE was deﬁned as systolic blood pressure ≥160 mm Hg or
diastolic blood pressure ≥110 mm Hg on at least 2 consecutive occa-
sions, 4 h apart; and proteinuria ≥2 g/l or at least 3+ protein by
dipstick. The normotensive pregnant women had systolic/diastolic
blood pressure b120/80 mm Hg and no history of hypertension or
proteinuria. The non-pregnant women had neither clinical alterations
nor a history of PE or hypertension [3].
2.1.2. Exclusion criteria
Exclusion criteria common to the 3 groups were chronic hyperten-
sion, hemostatic abnormalities, cancer, diabetes, obesity, and cardio-
vascular, autoimmune, renal, and hepatic diseases.
2.2. Ethical aspects
This study was approved by the Ethics Committee of Universidade
Federal de Minas Gerais (COEP), no. ETIC 0343.0.203.000-10, and
informed consent was obtained from all participants.
2.3. Blood samples
Blood samples were drawn in sodium citrate (0.129 mol/l) in a 9:1
volume ratio. The samples were centrifuged at 2500×g for 15 min to
obtain plasma. Samples were aliquoted and stored at −70 °C until
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Fig. 1. Identiﬁcation of plasma microparticles. (A) Microparticles isolated from the plasm
(B) Mouse IgG FITC and PE-conjugated isotype control monoclonal antibodies were used to2.4. Flow cytometry assay
MPs were prepared as described elsewhere [19]. Brieﬂy, samples
were centrifuged at 13,000×g for 3 min to obtain platelet-free plasma,
which was then diluted 1:3 in citrated phosphate buffered saline (PBS)
containing heparin and centrifuged at 14,000×g for 90 min at 15 °C.
The subsequent MP pellet was resuspended in 1× annexin V binding
buffer (Sigma-Aldrich, MO).
MPs isolated from plasma were gated on the basis of their forward
(FSC) and side (SSC) scatter distribution of synthetic 0.7–0.9 μm
SPHEROTM Amino Fluorescent Particles (Spherotech Inc., Libertyville,
IL, USA) (Fig. 1). Taking into account the presence of phosphatidylserine
residues on the MP surfaces, events present in the gate were assessed
for their positive staining for annexin V (Sigma-Aldrich) — a classical
marker for microparticles — using ﬂuorescein isothiocyanate (FITC)-
conjugated monoclonal antibodies against annexin V. Labeling with
cell-speciﬁc monoclonal antibodies was corrected for isotype-matched
control antibodies.
FITC-labeled immunoglobulin G1 (IgG1) and PE-labeled IgG1
isotype controls, monoclonal antibodies directed against neutrophils
(CD66-PE), endothelial cells (CD51-PE), monocytes (CD14–PERCP),
platelets (CD41–PERCP), leukocytes (CD45–APC), and erythrocytes
(CD235a–PECy5), were purchased from BD Biosciences® (CA, USA).
Monoclonal antibody directed against T lymphocytes (CD3-PE) was
purchased from Beckman Coulter Immunotech (Marseille, France).
We used the following combination: tube 1 — annexin FITC, CD66-PE,
CD45–APC, CD14–PERCP; tube 2 — annexin FITC, CD41–PERCP,
CD3-PE and tube 3 — annexin FITC, CD235a–PECy5, CD51-PE.
A placentalMP assessmentwas performed using an indirect staining
procedure. NDOG2 (speciﬁc primary antibody; BD Biosciences®, San
Jose, CA) and a goat anti-mouse IgM secondary antibody PE-conjugate
(Thermo Scientiﬁc®, Fairlawn, NJ) were used. MPs were incubated
with unlabeled NDOG2, washed with PBS, and incubated with second-
ary antibody PE.
The samples were analyzed for 60 s in a Flow Cytometry
FACSCalibur (Becton-Dickinson). The following ﬁnal dilutions of anti-
bodies were used: anti-CD235a–PECy5 (1:400), NDOG2 (1:20), and
anti-mouse IgM secondary antibody (1:25). The other antibodies
were used in concentrations according to each manufacturer's
instructions.
2.5. Determination of MP plasma levels
To investigate the absolute MP plasma levels and to determinate
the number of plasma MPs per microliter (MPs/μl), the cytometer
was set to operate at a high ﬂow rate setting for 60 s for each sample.104
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a were gated on the basis of their forward (FSC) and side (SSC) scatter distribution.
accurately place the gates.
Table 1
Characteristics of the women studied.
Characteristic Severe PE
(n=28)
Normotensive
pregnant
(n=30)
Nonpregnant
women
(n=29)
P value
Age (y) 29 (26–34) 24 (20–28) 22 (18–30) 0.008a
BMI 25.2±5.4 24.6±4.1 22.6±3.5 0.009b
GA (weeks) 33.5±3.7 33.9±3.9 − NSc
SBP (mm Hg) 170 (160–180) 100 (100–110) 120 (110–120) b0.001a
DBP (mm Hg) 110 (100–120) 70 (70–75) 80 (70–80) b0.001a
Parity
Nulliparous 11 (39%) 10 (33%) 12 (41%) NS
Multiparous 17 (61%) 20 (67%) 17 (59%)
Age, SBP: systolic blood pressure and DBP: diastolic blood pressure. Values are
presented as median (25th–75th percentiles). GA: gestational age. Values are
presented as mean±standard deviation. (−): does not apply. Signiﬁcant difference
when Pb0.05. NS: non signiﬁcant.
a Kruskal–Wallis test.
b Anova.
c T test.
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MPs/μl=(N×400)/(60×100), in which N=number of events,
400=total volume of sample in the tube before analysis, 60=sample
volume analyzed, and 100=original volume of MP suspension.
2.6. Statistical analysis
Statistical analyses were performed using SPSS software version
13.0 (SPSS Inc., Chicago, IL). Shapiro–Wilk tests were used to verify if
the variables were normally distributed. Data not normally distributed
were compared using the Kruskal–Wallis test. Comparison between 2
groupswas done using theMann–WhitneyU testwith Bonferroni's cor-
rection (non-normal data) or t-test (normal data). Normal data are
presented asmean and standard deviation, while non-normal variables
are presented as median and interquartile range (25th–75th percen-
tiles). Correlations were analyzed using the Pearson or SpearmanTable 2
Cellular origin and number of circulating microparticles.
MPs Severe PE (I) Normotensive pre
Total 8.43 (1.60–30.48) 4.87 (1.23–19.20
Platelet 30.93 (11.08–86.92) 38.27 (11.43–132
Endothelial 36.77 (5.48–73.03) 28.67(3.55–95.48
Leukocyte 19.76 (5.20–63.77) 16.57 (2.70–58.07
Erythrocyte 12.77 (1.87–37.40) 5.27 (1.22–10.08
Neutrophil 9.13 (1.37–17.78) 3.00 (1.42–9.25)
Placenta 6.37 (1.62–12.45) 5.00 (1.00–13.08
Monocyte 1.93 (0.55–5.40) 1.53 (0.48–2.70)
Lymphocyte 0.90 (0.15–3.37) 1.20 (0.22–4.20)
Data are presented as median (25th–75th centiles), MPs/μl. *Differences between 2 groups (M
a = group I×group II.
b = group I×group III.
c = group II×group III.2-sided test and Pearson χ2 test to frequency differences. Differences
were considered signiﬁcant when Pb0.05.3. Results
The characteristics of the women enrolled in this study are summa-
rized in Table 1. The mean proteinuria value (g/l/24 h) for pregnant
women with PE was 4.16±2.1, conﬁrming the presence of severe PE.
All women with severe PE had signiﬁcantly increased systolic
(Pb0.001) and diastolic blood pressure (Pb0.001) compared with the
2 other groups.
No differences in gestational age were noted between the women
with severe PE and the normotensive pregnant women. Body mass
index before pregnancy did not differ among the 3 groups (P=0.009).
Differences were found in age among the 3 groups (P=0.008).
Most participants in the 3 groups were multiparous. Eleven (39%)
of the 28 women with severe PE were nulliparous. Five of the multi-
parous women had PE in their previous pregnancy. Eleven women
with PE had abnormal liver function markers or decreased platelets
counts but did not fulﬁll the criteria for HELLP syndrome (hemolysis,
elevated liver enzymes, and low platelet count). The most common
symptom among women with PE was headache (21 women), scoto-
mata (9), epigastric pain (3), and patellar reﬂex alteration (1).
Table 2 summarizes the cellular origin and number of circulating
MPs studied. A higher total number of MPs were observed in women
with severe PE compared with normotensive pregnant women
and non-pregnant women (P=0.004 and P=0.001, respectively).
However, the 2 last groups did not display different numbers of MPs
(P=0.154).
Normotensive pregnant and non-pregnant women showed higher
levels of circulating platelet-derived MPs. Unlike these 2 groups, most
circulating MPs in women with severe PE originated from the endo-
thelial cells. The number of erythrocyte-derived MPs was increased
in women with severe PE compared with normotensive pregnantgnant (II) Non-pregnant women (III) P value*
) 3.53 (0.80–14.73) 0.004a
0.001b
NSc
.93) 60.13 (11.87–129.80) NSa
NSb
NSc
) 7.93 (2.77–38.90) NSa
NSb
NSc
) 16.67 (4.43–79.70) NSa
NSb
NSc
) 2.73 (1.23–14.20) 0.002a
NSb
0.005c
3.47 (0.63–8.60) NSa
NSb
NSc
) 2.00 (0.17–3.03) NSa
0.002b
0.002c
1.00 (0.23–3.60) NSa
NSb
NSc
0.73 (0.13–2.53) NSa
NSb
NSc
ann–Whitney U test and Bonferroni correction). * Signiﬁcant: Pb0.05. NS: non signiﬁcant.
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women compared with non-pregnant women (P=0.005) (Fig. 2A).
Placenta-derived MPs (NDOG2-positive) were detected in the cir-
culation of women with severe PE and in normotensive pregnant
women. Curiously, some placenta-derived MPs were detected in
non-pregnant women. However, those levels were lower than what
was seen in the women with severe PE or normotensive pregnant
women (P=0.002 in both cases) (Fig. 2B).
No signiﬁcant differenceswere observed among the3 groups regard-
ing the number of platelet-, endothelium-, leukocyte-, neutrophil-,
monocyte-, and T lymphocyte-derived MPs. Nevertheless, there was a
clear reduction in platelet-derived MP levels in women with severe PE
and normotensive pregnant women but an increase in neutrophil- and
endothelial cell-derived MPs in women with severe PE.
Correlation analysis showed no correlation between MP levels and
gestational age or systolic/diastolic blood pressure considering all
types of MPs in women with PE (P>0.05). Similarly, no correlation
was found among trophoblast-, endothelial cell-, and platelet-
derived MPs (P>0.05). No correlation was found between platelet-,
erythrocyte-, and leukocyte-derived MPs and their respective cell
numbers in the circulation of women with PE. However, we observed
a trend towards association between platelet count (categorized
according to cutoff=150,000/mm3) and the number of MPs derived
from platelets (categorized considering the median of the control
group) (P=0.09).
Positive correlationswere found between the number of endothelial
cell-derived MPs and platelet-derived MPs (r=0.483; P=0.009),Q5
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Fig. 2. Flow cytometry plots of microparticles derived from erythrocytes (A) and trophoblast
preeclampsia.leukocyte-derived MPs (r=0.519; P=0.005), neutrophil-derived MPs
(r=0.394; P=0.038), and T lymphocyte-derived MPs (r=0.616;
Pb0.001) in PE group.
4. Discussion
This study showed that MPs were signiﬁcantly increased in women
with severe PE compared with normotensive pregnant women and
non-pregnant women. Similarly, Lok et al. [21] and Orozco et al. [22]
demonstrated higher number of MPs in women with PE compared
with normotensive pregnant women.
The majority of circulating MPs detected in severe PE were derived
from endothelial cells, while most MPs in normotensive pregnant
women and non-pregnant women were derived from platelets.
Although we observed a reduced number of platelet MPs in women
with severe PE compared with non-pregnant women, this difference
was not signiﬁcant, probably due to the high dispersion of the data in
this variable. Similarly, Alijotas-Reig et al. [23] found no difference in
platelet-derived MPs in women with severe PE vs. non-pregnant
women. However, there was a positive correlation between platelet-
derived MPs and platelet cell count when these variables were catego-
rized. Lok et al. [24] also noted a reduction in platelet-derived MPs in
women with severe PE and a correlation with platelet count.
The number of platelet-derived MPs may reﬂect the turnover of
platelets in the plasma. Although platelet activation has been ob-
served in PE, we were not able to identify increased number of
platelet-derived MPs. A possible explanation for this ﬁnding couldQ5
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frequently evidenced in the placental microvasculature of women
with severe PE [23]. Therefore, a lower platelet count in severe PE is
associated with exacerbated platelet activation and high consump-
tion [23,25]. Thus, the decreased platelet counts in PE may explain
the decreased number of this MP type [24].
PE is believed to be a disorder of the maternal endothelium [6].
Although there was a tendency for a higher number of endothelial
cell-derived microparticles in women with severe PE compared with
normotensive pregnant women and non-pregnant women, the differ-
ence was not signiﬁcant. Contrarily, González-Quintero et al. [26] docu-
mented higher number of endothelial cell-derived MPs in women with
PE compared with women with gestational hypertension and non-
pregnant women. Endothelial cell activation may contribute to both in-
ﬂammatory response and vasoconstriction. In the kidney, the endothe-
lial defect can cause proteinuria and endothelium-dependent dilatation
failure, which can contribute to hypertension and intense vasoconstric-
tion in different organs [6]. Therefore, endothelium activation should be
detectable by an increased number of endothelial cell-derived MPs in
the circulation using more highly speciﬁc MPs [27]. Although we were
not able to show a signiﬁcant increase in the number of endothelial
cell-derived MPs in women with severe PE compared with the other
groups, the number of endothelial cell-derived MPs was associated
with higher levels of lymphocyte-, leukocyte-, and platelet-derived
MPs, which suggests a correlation between endothelium activation
and these cell types [15].
Our data showed increased number of erythrocyte-derived MPs in
women with severe PE. This ﬁnding could be explained by hemolysis,
which is commonly observed in this disease [28]. Because ﬁbrin clots
have been observed in the microvasculature of women with PE, one
hypothesis is that erythrocytes are lysed by colliding with such clots
and result in MP release [29]. However, no correlation between
erythrocyte-derived MPs and erythrocyte number in the circulation
was found.
Our data do not reveal signiﬁcant differences in leukocyte-,
monocyte-, lymphocyte-, and neutrophil-derived MPs, although there
was a tendency toward increased number of neutrophil-derived MPs
in women with severe PE. In contrast, monocyte-, lymphocyte-, and
neutrophil-derived MPs were previously determined to be associated
with PE [24,30,31]. Elevated number of leukocyte-derived MPs may re-
ﬂect activation of these cells because this disease is associated with the
local inﬂammatory response that results in an enhanced leukocyte en-
dothelial interaction [32].
Stallmach et al. [33] observed higher number of activated lympho-
cytes in the placentas of women with severe PE, which could generate
increased number of MPs released into the maternal circulation.
Leukocyte-derived MPs induce endothelial cell and cytokine gene acti-
vation. This may be a mechanism for ampliﬁcation of the local concen-
tration of inﬂammatory and chemotactic cytokines and induction of
adhesion molecule-facilitated intercellular communication and cross-
signaling between leukocytes and endothelial cells [34]. Leukocyte-
derived MPs cause endothelial damage, which could explain the corre-
lation between neutrophil-, leukocyte-, and lymphocyte-derived MPs
and endothelial-derived MPs observed in this study [30].
The placenta has been shown to play an important role in the
pathogenesis of PE. Trophoblast invasion is impaired, which results
in placental factor release in the maternal circulation that causes
generalized vascular dysfunction [35]. Syncytiotrophoblast (STBM)-
derived MPs have been considered a candidate for this factor, mainly
because increased trophoblast apoptosis was observed in PE [36,37].
Our data showed that a number of placenta-derived MPs were not
signiﬁcantly elevated in women with severe PE compared with
normotensive pregnant women. However, there were an elevated
number of placenta-derived MPs in women with severe PE and nor-
motensive pregnant women compared with non-pregnant women.
This ﬁnding is in contrast to the ﬁndings of other authors, whoreported an elevated number of placenta-derived MPs in women
with PE compared with normotensive pregnant women [17,38].
NDOG-2 is a speciﬁc antibody that recognizes placental alkaline
phosphatase [36]. Similar to the study of Vanwijk et al. [30], we
used the NDOG2 antibody to detect and quantify STBM. These anti-
bodies bound to placenta-derived MPs in both women with severe
PE and normotensive pregnant women. However, some NDOG-2
was detected in non-pregnant women, even in women who had
never been pregnant. This ﬁnding suggests that NDOG2 is not
STBM-speciﬁc and could explain these opposite results comparing
previous studies [30]. Despite this low speciﬁcity, the high capacity
of these MPs to damage the vascular endothelium or to activate neu-
trophils should be considered [39]. Moreover, trophoblast-derived
MPs bind to monocytes and B cells, stimulate the production of in-
ﬂammatory cytokines, and may be related to placental ischemia and
oxidative stress [38,40,41].
In conclusion, a higher number of endothelial cell-derived MPs in
womenwith severe PE suggest endothelium activation. Therefore, the
level of erythrocyte-derived MPs is increased in preeclampsia. In the
future, new therapeutic targeting erythrocyte-derived MPs could be
proposed. However, considering the limited sample of the current
study, other studies are needed to elucidate the mechanisms involved
in their effects to contribute to additional intervention strategies for
the management of severe PE.
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